Why the study?
Does nifedipine upregulate Mn SOD expression in vascular smooth muscle cells via endothelial cell-dependent pathways?
Does nifedipine upregulate Mn SOD expression in vascular smooth muscle cells via endothelial cell-dependent pathways?
Nifedipine upregulates the antioxidant enzyme Mn SOD in vascular smooth muscle cells via nitric oxide derived from endothelial cells, providing insight into its vascular protective mechanisms.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for nifedipine’s endothelial NO-mediated antioxidant effects; does not support clinical practice changes.
Calcium antagonists normalize endothelial dysfunction and improve the clinical outcome in patients with hypertension. However, the mechanism underlying these beneficial effects remains to be elucidated. Here, we show that the calcium antagonist nifedipine upregulates the expression of manganese superoxide dismutase (Mn SOD), an endogenous antioxidant enzyme, in vascular smooth muscle cells (VSMC) via cellular interactions between VSMC and endothelial cells (EC). Nifedipine induced upregulation of Mn SOD activity and expression in VSMC when cocultured with EC but not when cultured individually. NG-Monomethyl-L-arginine (L-NMMA), an inhibitor of nitric oxide (NO) synthesis, inhibited the upregulation of Mn SOD expression induced by nifedipine. Additionally, N-ethyl-2-(1-ethyl-2-hydroxy-2-nitrosohydrazino) ethanamine, a NO donor, reversed this inhibition by L-NMMA, indicating that NO may be involved in the mechanism underlying the nifedipine-induced upregulation of Mn SOD in VSMC. Preincubation of VSMC with Mn SOD antisense oligodeoxyribonucleotides (ODN) blocked the suppressive effects of nifedipine on DNA synthesis in VSMC cocultured with EC, whereas sense ODN had no effect. We conclude that the calcium antagonist nifedipine induces upregulation of Mn SOD expression in VSMC via NO derived from EC. This finding may provide some insight into the mechanism underlying the beneficial effects of calcium antagonists in patients with hypertension.
No takes yet. Share an insight, caveat, or question.
Fukuo et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: